In this article, Nina Patrick, Ph.D.
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
Optimi Health has entered into a long-term distribution agreement with Mind Medicine Australia to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules.
In this article, Nina Patrick, Ph.D.,
PharmAla Biotech Holdings has been named the exclusive supplier of both GMP and engineering MDMA to Awakn LS Europe Holdings Limited.
Using machine learning analysis, researchers have determined that a mystical and insightful psychedelic drug experience may be linked to long-term reductions in anxiety and depression symptoms.
With an increase in psychedelic research and clinical trials, it is becoming increasingly important to train psychedelic therapists.
Awakn Life Sciences has confirmed it has signed its fourth Licensing Partnership agreement in North America with Ken Starr MD Wellness Group, an addiction treatment facility...
As psychedelic research increases, and a number of policy developments across the likes of the US, Canada and Australia are now enabling the delivery of psychedelic...
University of Cincinnati researchers have examined post-treatment journals kept by participants in a smoking cessation study that found psychedelics were effective in helping some people quit...